Accentia Biopharmaceuticals’ Majority-Owned Subsidiary, Biovest International, Inc., and VWR International, Inc. Enter Into Marketing and Distribution Agreement for AutovaxID

TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB:BVTI) a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has entered into a distribution agreement with VWR International, Inc., to distribute its breakthrough AutovaxID™ automated cell culture device in North America. The company believes that this agreement will provide AutovaxID with a preferred position in the market and allow the AutovaxID to achieve rapid market penetration. VWR plans to begin its sales and marketing activities of this product line in July 2007.